RxDoctor Payments Data

Raja Chakrapani, MD

Internal Medicine · Turtle Creek, PANPI 1366424541

Payments from drug & device makers

$1,605in general payments, 2019–2025

Across 35 payments — averaging $45.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$534
  • Johnson & Johnson$337
  • Lilly USA, LLC$248
  • Sanofi-aventis U.S. LLC$162
  • Boston Scientific$121
  • Amgen$115
  • plus $88 from 2 others

What the payments were for

  • Food & beverage$1,56097%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,605 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$255,471
Medicare patients
361
Services billed
2,596

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban727$345,005
Invega SustennaPaliperidone Palmitate98$314,350
JardianceEmpagliflozin262$153,503
IngrezzaValbenazine Tosylate29$133,305
Trelegy ElliptaFluticasone/Umeclidin/Vilanter176$116,258
Breo ElliptaFluticasone/Vilanterol223$95,352
OzempicSemaglutide77$78,809
TrulicityDulaglutide64$66,229
XareltoRivaroxaban125$57,473
EntrestoSacubitril/Valsartan100$49,409
JanuviaSitagliptin Phosphate85$46,182
Aripiprazole297$38,931
LatudaLurasidone Hcl26$37,339
VraylarCariprazine Hcl26$36,228
Abilify MaintenaAripiprazole12$34,843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto$337$371,823223 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$534$230,542451 claims
Lilly USA, LLCTrulicity, Mounjaro$248$93,00585 claims
AbbVieVraylar, Creon$47$46,75539 claims
AstraZenecaFarxiga, Brilinta$41$28,53968 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Turtle Creek

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →